

Advaxis, Inc.  
Form 8-K  
December 15, 2016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **December 15, 2016**

**ADVAXIS, INC.**

(Exact Name of Registrant as Specified in Charter)

<b>Delaware</b>	<b>000-30929</b>	<b>13-4087132</b>
(State or Other Jurisdiction)	(Commission File Number)	(IRS Employer Identification No.)

of Incorporation)

**305 College Road**

**Princeton, New Jersey 08540**

(Address of Principal Executive Offices)

**(609) 452-9813**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act.
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
- Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

The Company is announcing that Gregory T. Mayes, Executive Vice President and Chief Business Officer, has resigned from the Company in order to pursue a business opportunity focused on the development of a treatment for epileptic seizures, a condition that affects an immediate family member. The resignation will be effective as of December 30, 2016. Mr. Mayes will continue to serve as a Director on the Company's Board of Directors.

The Company is also announcing the promotion of Sara Bonstein, the Company's Chief Financial Officer, to Executive Vice President. The promotion will be effective as of December 30, 2016.

- 2 -

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Advaxis, Inc.**  
(Registrant)

Date: December 15, 2016

By: */s/ Daniel O'Connor*  
Daniel O'Connor  
President and Chief Executive Officer

